Japan okays GSK’s Sotrovimab for treating Covid-19 patients. (Reuters)
<p>
Japan has approved GlaxoSmithKline and Vir Biotechnology&#39;s Sotrovimab medicine as an antibody treatment for coronavirus, Health Minister Norihisa Tamura said on Monday.</p>
<p>
The antibody treatment is for mild to moderate COVID-19 cases which do not require oxygen supplementation, GSK said when it applied for fast-track approval this month.</p>
<p>
Sotrovimab has already been granted an emergency use approval by the FDA to facilitate the availability and use of this investigational monoclonal antibody for the treatment of COVID-19 in the U.S.</p>
<p>
GSK had claimed interim study results demonstrated an 85% reduction in hospitalisation for more than 24 hours or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial</p>
In a retaliatory move, China on Wednesday announced it will increase its tariff on US…
President Droupadi Murmu held a meeting with her Slovakian counterpart Peter Pellegrini in Bratislava on…
Union Minister for Agriculture & Farmers' Welfare and Rural Development, Shivraj Singh Chouhan, led a…
External Affairs Minister S Jaishankar on Wednesday expressed concerns about radicalizing tendencies, attacks on minorities,…
A tragic traffic accident in the Bagardo area of Pakistan-occupied Gilgit-Baltistan (PoGB) has once again…
A sharp rise in alleged extrajudicial killings of forcibly disappeared individuals in Balochistan has sparked…